Past Accomplishments and Ongoing Initiatives
We filed a provisional patent for a reusable 4-layer all-natural cotton / silk general-purpose face mask that creates a self-sustaining tribo-electric gram-positive charge that is intended to neutralize gram-negative microbes. The video at left details the technology and scientific underpinnings of the face covering. We had biological laboratory testing of the Stay Safer face covering performed but delayed conducting filtration and leakage testing pending updates to the ASTM Barrier Face Covering standard's requirements.
2021 - 2022
Until recently, there existed no examination of the relative cost of novel multi-drug anticancer treatments vs. traditional therapy options, or study as to how knowledge about comparative treatment costs at the point-of-care could be leveraged by doctors, health systems, and payers.
Our March 2022 study challenges common misconceptions about combination cancer treatments, their cost and value. It gives payers, providers and patients important insight as to how to better select medications that are likely to be more effective and avoid wasteful spending on hugely expensive, low-clinical-value drugs.
Gaining Control of Combination Cancer Treatment Risk by Incorporating Cost and Value Data into the Drug Selection Process at the Point-of-Care shows why there is no longer a reason to continue the practice of uninformed, high-stakes oncology prescribing given the emergence of Healthcare AI that can guide drug selection and drive value for payers and patients alike. It is available for download by clicking on the image above or on MedRxiv here or ResearchGate here.
Equipping Payers to Outsmart Cancer with Game-Changing Healthcare AI describes why payers must embrace the torrent of medical and technological advances that are changing the way we now approach, treat and survive cancer.
Intended for non-clinician payer executives* this presentation explains what cancer really is; new ways to defeat it; why the FDA approval process can't be relied upon to assess new high-cost, low-clinical-value Rxs; and why payers are leveraging Healthcare AI to improve patient outcomes, cut wasteful spending and extend value-purchasing to include oncology specialty pharmacy.